Eli Lilly & Co. (NYSE:LLY) Gets Dedicated Humulin R U-500 Insulin Syringe From Becton Dickinson

Eli Lilly

Becton Dickinson (BD) has recently unveiled BD U-500 Insulin Syringe, a syringe dedicated to the Humulin R U-500 insulin of Eli Lilly & Co. (NYSE:LLY).

Story continues below

BD U-500 Insulin Syringe

The BD U-500 Insulin Syringe is specifically designed to administer the Humulin R U-500 insulin among patients properly.

The Humulin R U-500 insulin is prescribed to patients who need a higher dose of insulin on a daily basis. It has five times the insulin compared to common insulin, meeting the needs of patients whose bodies at insulin resistant.

Prior to the the BS U-500 Insulin Syringe, they had to settle and risk with traditional syringes since the launch of the Humulin R U-500 insulin in 1994. Patients and healthcare providers had to calculate dose conversations thoroughly in order to administer the correct dosage using traditional syringes. Administering the incorrect dosage can potentially lead to fatalities.

“At Lilly, we recognize that people with diabetes have diverse needs and that their insulin delivery devices should reflect their individual needs, and we’re pleased to partner with BD to provide a dedicated U-500 insulin syringe,” emphasized Jeffrey Jackson, Ph.D., a US Medical Affairs Medical Fellow at Lilly Diabetes.

Presentation of New Data from Clinical Development Programs

In other news, Eli Lilly will present at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting, which will begin on Friday. The company will present new safety and efficacy data from Phase III clinical trials evaluating baricitinib and other new data from other clinical development programs seeking to treat rheumatoid arthritis (RA). The company will also present six abstracts and an oral presentation featuring results from the Phase III clinical trial evaluating Taltz (ixekizumab) for the treatment of patients with moderate-to-severe active psoriatic arthritis and plaque psoriasis.

Eli Lilly believes that its efforts will not just expand its portfolio but will most importantly improve patient care.

On Wednesday, Eli Lilly surged 5.90% to $78.39.

An ad to help with our costs